for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

EMA accepts Biogen's Alzheimer's treatment aducanumab for review

Oct 30 (Reuters) - Biogen Inc and partner Eisai Co Ltd said on Friday the European health regulator has accepted for review the marketing application for its closely-watched experimental Alzheimer’s treatment aducanumab.

Aducanumab is also under review with the U.S. Food and Drug Administration. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up